Direct costs of brain disorders make up for 60% of the total costs – which EBC estimated at 800 bln€/year in Europe. At European level, this health budget far exceeds that of cardiovascular diseases, brain diseases and diabetes together. ALAMEDA will research, develop and exploit the next generation of personalized AI healthcare support systems that improve the rehabilitation treatment of Parkinson’s, Multiple Sclerosis, and Stroke (PMSS) patients. Stemming from very specific clinical use cases, ALAMEDA will develop user-friendly solutions that will be designed and evaluated on the principles of value-based health. The consortium brings together established medical research teams, AI researchers, medical software vendors and healthcare market experts to demonstrate AI-based personalised prediction, prevention, and intervention approach in three (3) real world pilots. Liaisons have been established with projects MULTI-ACT and IDEA-FAST and the carefully structured workplan, embodies an integrated and harmonized approach with active patients’ engagement towards meeting the ALAMEDA objectives and delivering market-relevant outcomes of significant exploitation potential.